Rapport Therapeutics (NASDAQ:RAPP) Stock Price Target Cut by UBS Group

Rapport Therapeutics (NASDAQ:RAPP) had its target price reduced by stock analysts at UBS Group from $71.00 to $64.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group‘s price objective suggests a potential upside of 161.87% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Citigroup reissued an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. William Blair assumed coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating on the stock. Guggenheim decreased their price objective on shares of Rapport Therapeutics from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday. Wells Fargo & Company dropped their target price on shares of Rapport Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, Wolfe Research assumed coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They issued an “outperform” rating and a $50.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $64.50.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP traded up $0.72 during midday trading on Thursday, reaching $24.44. 866,406 shares of the company’s stock were exchanged, compared to its average volume of 1,444,809. Rapport Therapeutics has a 52-week low of $22.06 and a 52-week high of $52.93. The business’s fifty day moving average price is $34.16 and its two-hundred day moving average price is $35.53. The stock has a market capitalization of $1.17 billion, a PE ratio of -7.71 and a beta of 1.40.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.36. Analysts predict that Rapport Therapeutics will post -3.90 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Abraham Ceesay sold 28,958 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer owned 486,108 shares in the company, valued at $23,338,045.08. This represents a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James Healy bought 969,480 shares of the firm’s stock in a transaction on Wednesday, October 28th. The stock was bought at an average price of $21.00 per share, with a total value of $20,359,080.00. Following the completion of the purchase, the director owned 2,815,707 shares of the company’s stock, valued at $59,129,847. This trade represents a 52.51% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 1,031,174 shares of company stock worth $22,023,898 and sold 97,976 shares worth $4,391,729. Corporate insiders own 12.48% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RAPP. TRV GP V LLC acquired a new position in shares of Rapport Therapeutics during the second quarter valued at $261,709,477. ARCH Venture Management LLC acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $155,376,512. BlackRock Inc. bought a new stake in Rapport Therapeutics in the 2nd quarter valued at about $112,500,000. Johnson & Johnson bought a new stake in Rapport Therapeutics in the 2nd quarter valued at about $74,360,823. Finally, TRV GP VI LLC acquired a new position in Rapport Therapeutics during the 2nd quarter valued at about $40,387,314.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2030 and for each quarter of 2027, projecting smaller losses than previously expected. For example, its FY2027 loss estimate improved to $4.29 per share from $6.80. The firm reiterated its Buy rating and $66 price target, a potentially supportive signal for investor sentiment. HC Wainwright estimate revisions
• Negative Sentiment: UBS lowered its price target to $64 from $71, and Guggenheim cut its target to $66 from $70. Both firms retained Buy ratings, but the reductions indicate more cautious valuation expectations. UBS price-target change

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.